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GnRH agonist is not required for frozen embryo transfers conducted under artificial 
hormone therapy 
 
To the Editor 
 
We were interested to read the paper by the group from Brussels (van de Vijver et al., 
2014) as it supports our view that GnRH agonist down-regulation is quite unnecessary 
in cryopreserved transfer cycles conducted under an artificial hormonal regimen. 
 
In the Australian and New Zealand setting, both safety and efficiency issues are major 
considerations in the practice of ART so that the vast majority of IVF cycles are now 
single embryo transfers (76.3% in 2012; Macaldowie et al, 2014). As a consequence, 
more embryos are cryopreserved and, overall, frozen-thawed embryo transfers (FET) 
result in an equivalent birth rate to that obtained following fresh transfers (22.2% 
versus 22.8%, respectively). At 6.5%, Australia and New Zealand share one of the 
lowest rates of multiple births in the world. 
 
In the PIVET Medical Centre facility in Perth, we can report the highest live birth rate 
for autologous thaw cycles of the 78 fertility units contributing to the Australian and 
New Zealand Assisted Reproduction Database (ANZARD), being 32.0% of cycles 
initiated overall and 42.5% for women under 35 years (see Table 19 of the 2012 
ANZARD report which shows the quartile ranges for all the fertility units, sub-
calculated for age ranges of the women; Macaldowie et al, 2014). 
 
Against this background, PIVET has increasingly performed FET procedures using an 
artificial model similar to that used by the Brussels group, as the efficiency for 
management of the fertility clinic is cost-beneficial. FET procedures can be allocated 
to specific favourable days during the week, with Sundays and holidays being 
completely avoided without compromising pregnancy chances. 
 
Furthermore the cycles can be conducted with minimal monitoring and be quite 
inexpensive for patients. In this context we have avoided the use of GnRH down-
regulation but, in response to the challenge by a reviewer of one of our reports 
concerning FET outcomes, we have now completed a series of hormonally monitored 
cycles. Over a recent six-month period only one case out of 250 cycles showed an 
elevation in serum progesterone concentration >5 nm/l on the final day of the artificial 
“follicular” phase, i.e. the day prior to commencing progesterone pessaries for the 
artificial “luteal” phase. 
 
We fully accept that endometrial synchrony is the key to successful embryo 
implantation, but we concur with the Brussels group in believing GnRH analogues are 
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